Parlux Q1
This article was originally published in The Rose Sheet
Executive Summary
Divestiture of Animale fragrance brand and a reduction in Jockey fragrance sales due to difficult comparison with the year-ago period contributed to 14.5% decline in net sales to $16.9 mil. for the first quarter (ended June 30), Parlux announces Aug. 13. Loss of sales from Animale equaled $1.8 mil., while sales of Jockey fragrances declined $1.1 mil. compared with last year, firm notes. Net income fell 35.7% to $717,344 despite reduced spending due to lower sales and product mix, firm adds. Parlux also markets Perry Ellis and Ocean Pacific fragrances...
You may also be interested in...
Parlux
Net sales grew 12% to $80.5 mil. in fiscal 2004 (ended March 31), firm reports. Net income was up 14% to $6.3 mil., and diluted earnings per share rose 17% to $.63. "We are pleased with our sales increase considering that prior year sales include over $6 mil. of brands which were sold/sublicensed during that period," Chairman and CEO Ilia Lekach states. "Excluding those brands, our sales increase would have exceeded 22%, which confirms the strength of our core business," exec adds. Parlux divested the Animale brand and reduced sales of Jockey fragrances last year (1"The Rose Sheet" Aug. 18, 2003, In Brief). Firm anticipates launches of Guess and Paris Hilton fragrances will drive growth going forward...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.